[Outcome parameters for use in psoriatic arthritis]

Area of Science:

• Rheumatology
• Dermatology
• Immunology

Background:

• Psoriasis vulgaris is the most common form of psoriasis.
• Palmoplantar pustulosis is significant in rheumatology.
• Psoriatic arthritis (PsA) encompasses joint, spinal, and nail manifestations associated with psoriasis.

Purpose of the Study:

• To highlight the importance of defining outcome parameters for psoriatic arthritis (PsA).
• To discuss the varied clinical presentations of PsA, often overlapping with spondyloarthropathies (SpA) and rheumatoid arthritis (RA).
• To emphasize the need for PsA-specific outcome measures considering new treatments.

Main Methods:

• Review of clinical features and outcome parameters in psoriatic arthritis.
• Comparison of PsA manifestations with spondyloarthropathies (SpA), rheumatoid arthritis (RA), and osteoarthritis (OA).
• Analysis of key outcome domains including clinical signs, function, structure, skin/nail involvement, and quality of life.

Main Results:

• PsA presents with diverse clinical pictures, frequently including asymmetric oligoarthritis, enthesitis, and spinal inflammation.
• Characteristic PsA features include dactylitis, ray-wise joint involvement, and osteodestructive/proliferative changes.
• Current outcome parameters are varied, with a lack of PsA-specific instruments, often relying on SpA or RA measures.

Conclusions:

• PsA requires distinct outcome parameters that account for its unique clinical spectrum, including skin and nail involvement.
• Standardized, PsA-specific outcome measures are essential for evaluating treatment efficacy and guiding patient care.
• Further development of measuring instruments tailored to PsA is necessary given its complexity and evolving treatment landscape.